Rhythm Pharmaceuticals (RYTM) Competitors $60.10 +0.55 (+0.92%) As of 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, ROIV, LNTH, and TGTXShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Lantheus (LNTH), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Lantheus TG Therapeutics Rhythm Pharmaceuticals (NASDAQ:RYTM) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership. Which has stronger valuation and earnings, RYTM or SMMT? Rhythm Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M29.20-$184.68M-$4.35-13.82Summit Therapeutics$700K27,536.54-$614.93M-$0.31-84.29 Do insiders and institutionals have more ownership in RYTM or SMMT? 4.6% of Summit Therapeutics shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in RYTM or SMMT? Rhythm Pharmaceuticals received 1 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 68.06% of users gave Rhythm Pharmaceuticals an outperform vote while only 58.44% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes30968.06% Underperform Votes14531.94% Summit TherapeuticsOutperform Votes30858.44% Underperform Votes21941.56% Is RYTM or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Summit Therapeutics' return on equity of -85.42% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Summit Therapeutics N/A -85.42%-52.66% Does the media refer more to RYTM or SMMT? In the previous week, Rhythm Pharmaceuticals had 22 more articles in the media than Summit Therapeutics. MarketBeat recorded 32 mentions for Rhythm Pharmaceuticals and 10 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.88 beat Rhythm Pharmaceuticals' score of 0.59 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 12 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RYTM or SMMT? Rhythm Pharmaceuticals has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Do analysts recommend RYTM or SMMT? Rhythm Pharmaceuticals currently has a consensus target price of $74.92, indicating a potential upside of 24.66%. Summit Therapeutics has a consensus target price of $35.40, indicating a potential upside of 35.48%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySummit Therapeutics beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Remove Ads Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.80B$6.38B$5.36B$7.62BDividend YieldN/A3.20%5.11%4.33%P/E Ratio-13.886.8221.7117.82Price / Sales29.20229.21376.1094.32Price / CashN/A65.6738.1534.64Price / Book20.945.896.444.00Net Income-$184.68M$141.32M$3.20B$247.24M7 Day Performance9.35%4.90%6.23%5.82%1 Month Performance17.91%-13.09%-6.64%-5.82%1 Year Performance49.02%-14.94%8.19%-1.90% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals4.1698 of 5 stars$60.10+0.9%$74.92+24.7%+47.7%$3.80B$130.13M-13.88140SMMTSummit Therapeutics2.3417 of 5 stars$17.32-0.2%$35.40+104.4%+534.1%$12.78B$700,000.00-61.85110Gap UpGMABGenmab A/S3.874 of 5 stars$18.19-1.1%$41.33+127.2%-35.7%$12.04B$21.53B10.451,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.3161 of 5 stars$12.59+1.8%$17.00+35.1%-7.5%$10.51B$311.31B20.0424,800Positive NewsHigh Trading VolumeMRNAModerna4.2366 of 5 stars$25.64+2.1%$59.00+130.1%-75.1%$9.91B$3.20B-2.763,900Positive NewsGap UpVTRSViatris2.7588 of 5 stars$7.61-0.1%$10.50+38.0%-33.5%$9.08B$14.74B-10.2837,000High Trading VolumeQGENQiagen3.4677 of 5 stars$40.33+5.4%$47.71+18.3%+7.5%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.2 of 5 stars$140.14-1.8%$204.64+46.0%+3.4%$8.50B$363.64M-19.741,017Positive NewsROIVRoivant Sciences2.5436 of 5 stars$9.26-2.1%$17.50+89.0%-9.9%$6.61B$122.59M-61.73860Positive NewsGap DownHigh Trading VolumeLNTHLantheus4.3905 of 5 stars$95.45+5.0%$129.43+35.6%+67.8%$6.54B$1.53B15.88700Positive NewsTGTXTG Therapeutics3.2698 of 5 stars$37.25-0.3%$40.67+9.2%+159.3%$5.85B$329.00M-372.46290Positive News Remove Ads Related Companies and Tools Related Companies Summit Therapeutics Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Lantheus Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersThe biggest story CNBC isn't talking about (yet)This Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
